1
|
Schrempft S, Pullen N, Baysson H, Wisniak A, Zaballa ME, Pennacchio F, Vollenweider P, Marques-Vidal P, Preisig M, Guessous I, Stringhini S, Arm-Vernez I, Azman AS, Ba F, Bachmann D, Bal A, Balavoine JF, Balavoine M, Barbe RP, Baysson H, Beigbeder L, Berthelot J, Bleich P, Boehm L, Bryand G, Bucolli V, Chappuis F, Collombet P, Courvoisier D, Cudet A, Davidovic V, de Mestral Vargas C, D'ippolito P, Dubos R, Dumont R, Eckerle I, El Merjani N, Flahault A, Francioli N, Frangville M, Graindorge C, Guessous I, Harnal S, Hurst S, Kaiser L, Kherad O, Lamour J, Lescuyer P, L'Huissier F, Lombard FB, Loizeau AJ, Lorthe E, Martinez C, Ménard L, Menon L, Metral-Boffod L, Meyer B, Moulin A, Nehme M, Noël N, Pennacchio F, Perez-Saez J, Pittet D, Portier J, Posfay-Barbe KM, Poulain G, Pugin C, Pullen N, Randrianandrasana ZF, Richard V, Rinaldi F, Rizzo J, Rochat D, Sakvarelidze I, Samir K, Santa Ramirez HA, Schrempft S, Semaani C, Stringhini S, Testini S, Rivas DU, Verolet C, Villers J, Violot G, Vuilleumier N, Wisniak A, Yerly S, Zaballa ME. Prevalence and predictors of psychological distress before, during, and after a COVID-19 pandemic wave in Switzerland, 2021. J Psychiatr Res 2023; 158:192-201. [PMID: 36592533 PMCID: PMC9794129 DOI: 10.1016/j.jpsychires.2022.12.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 10/04/2022] [Accepted: 12/22/2022] [Indexed: 12/28/2022]
Abstract
There are concerns about acute and long-term mental health effects of the COVID-19 pandemic. This study examined the prevalence and predictors of psychological distress before, during, and after a pandemic wave in Switzerland, 2021. Prevalence of psychological distress was estimated in adults aged 35-96 years using the General Health Questionnaire-12 administered in June 2021 (Specchio-COVID19 cohort, N = 3965), and compared to values from 2003 to 2006 (CoLaus|PsyCoLaus cohort, N = 5667). Anxiety and depression were assessed from February to June 2021 using the Generalised Anxiety Disorder scale-2 and the Patient Health Questionnaire-2, respectively. Prevalence of psychological distress in June 2021, after the pandemic wave (16.0% [95% CI, 14.6%-17.4%]) was comparable to pre-pandemic levels (15.1% [14.0%-16.2%]). Anxiety and depression were highest at the start of the pandemic wave in February 2021, and declined from February to June with the relaxation of measures. Predictors of psychological distress included being younger, female, a single parent, unemployed, a change in working hours or job loss in the past 6 months, greater perceived severity and contagiousness of COVID-19, and self-reported post COVID-19. By June 2021, following a pandemic wave, prevalence of psychological distress in Switzerland was closer to pre-pandemic levels. These findings highlight the need for additional mental health support during times of stricter government policies relating to COVID-19; yet they also suggest that individuals can adapt relatively quickly to the changing context.
Collapse
Affiliation(s)
- Stephanie Schrempft
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland.
| | - Nick Pullen
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland
| | - Hélène Baysson
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Ania Wisniak
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland
| | - María-Eugenia Zaballa
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland
| | - Francesco Pennacchio
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland
| | - Peter Vollenweider
- Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Pedro Marques-Vidal
- Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Martin Preisig
- Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Idris Guessous
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Silvia Stringhini
- Division of Primary Care, Unit of Population Epidemiology, Geneva University Hospitals, Geneva, Switzerland; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland; University Centre for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Raptis CE, Berger CT, Ciurea A, Andrey DO, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022; 13:1016927. [PMID: 36311791 PMCID: PMC9606233 DOI: 10.3389/fimmu.2022.1016927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 09/20/2022] [Indexed: 12/03/2022] Open
Abstract
Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination strategies. We aimed to conduct a long-term, model-based comparison of the humoral immunogenicity following BNT162b2 and mRNA-1273 vaccination in a cohort of IRD patients. Patients from the Swiss IRD cohort (SCQM), who assented to mRNA COVID-19 vaccination were recruited between 3/2021-9/2021. Blood samples at baseline, 4, 12, and 24 weeks post second vaccine dose were tested for anti-SARS-CoV-2 spike IgG (anti-S1). We examined differences in antibody levels depending on the vaccine and treatment at baseline while adjusting for age, disease, and past SARS-CoV-2 infection. 565 IRD patients provided eligible samples. Among monotherapies, rituximab, abatacept, JAKi, and TNFi had the highest odds of reduced anti-S1 responses compared to no medication. Patients on specific combination therapies showed significantly lower antibody responses than those on monotherapy. Irrespective of the disease, treatment, and past SARS-CoV-2 infection, the odds of higher antibody levels at 4, 12, and 24 weeks post second vaccine dose were, respectively, 3.4, 3.8, and 3.8 times higher with mRNA-1273 versus BNT162b2 (p < 0.0001). With every year of age, the odds ratio of higher peak humoral immunogenicity following mRNA-1273 versus BNT162b2 increased by 5% (p < 0.001), indicating a particular benefit for elderly patients. Our results suggest that in IRD patients, two-dose vaccination with mRNA-1273 versus BNT162b2 results in higher anti-S1 levels, even more so in elderly patients.
Collapse
Affiliation(s)
- Catherine E. Raptis
- SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases), Zurich, Switzerland
| | - Christoph T. Berger
- University Center for Immunology and Immunization Clinic, University Hospital Basel, Basel, Switzerland
- Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Adrian Ciurea
- Department of Rheumatology, Zurich University Hospital, University of Zurich, Zurich, Switzerland
| | - Diego O. Andrey
- Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Christos Polysopoulos
- SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases), Zurich, Switzerland
| | - Pierre Lescuyer
- Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland
| | - Tanja Maletic
- SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases), Zurich, Switzerland
| | - Myriam Riek
- SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases), Zurich, Switzerland
| | - Almut Scherer
- SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases), Zurich, Switzerland
| | - Isabell von Loga
- SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases), Zurich, Switzerland
| | | | - Kim Lauper
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland
| | - Burkhard Möller
- Division of Rheumatology and Immunology, Inselspital, Bern University Hospital, Bern, Switzerland
| | - Nicolas Vuilleumier
- Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Axel Finckh
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland
| | - Andrea Rubbert-Roth
- Division of Rheumatology and Immunology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
- *Correspondence: Andrea Rubbert-Roth,
| |
Collapse
|
3
|
Steiner C, Lescuyer P, Cutler P, Tille JC, Ducret A. Relative Quantification of Proteins in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue Using Multiplexed Mass Spectrometry Assays. Mol Cell Proteomics 2022; 21:100416. [PMID: 36152753 PMCID: PMC9638817 DOI: 10.1016/j.mcpro.2022.100416] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 09/15/2022] [Accepted: 09/17/2022] [Indexed: 01/18/2023] Open
Abstract
The identification of clinically relevant biomarkers represents an important challenge in oncology. This problem can be addressed with biomarker discovery and verification studies performed directly in tumor samples using formalin-fixed paraffin-embedded (FFPE) tissues. However, reliably measuring proteins in FFPE samples remains challenging. Here, we demonstrate the use of liquid chromatography coupled to multiple reaction monitoring mass spectrometry (LC-MRM/MS) as an effective technique for such applications. An LC-MRM/MS method was developed to simultaneously quantify hundreds of peptides extracted from FFPE samples and was applied to the targeted measurement of 200 proteins in 48 triple-negative, 19 HER2-overexpressing, and 20 luminal A breast tumors. Quantitative information was obtained for 185 proteins, including known markers of breast cancer such as HER2, hormone receptors, Ki-67, or inflammation-related proteins. LC-MRM/MS results for these proteins matched immunohistochemistry or chromogenic in situ hybridization data. In addition, comparison of our results with data from the literature showed that several proteins representing potential biomarkers were identified as differentially expressed in triple-negative breast cancer samples. These results indicate that LC-MRM/MS assays can reliably measure large sets of proteins using the analysis of surrogate peptides extracted from FFPE samples. This approach allows to simultaneously quantify the expression of target proteins from various pathways in tumor samples. LC-MRM/MS is thus a powerful tool for the relative quantification of proteins in FFPE tissues and for biomarker discovery.
Collapse
Affiliation(s)
- Carine Steiner
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland,BiOmics and Pathology, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, Switzerland,For correspondence: Carine Steiner
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland,Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Paul Cutler
- BiOmics and Pathology, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, Switzerland
| | - Jean-Christophe Tille
- Division of Clinical Pathology, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland
| | - Axel Ducret
- BiOmics and Pathology, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, Switzerland
| |
Collapse
|
4
|
Smit C, Sen S, von Dach E, Karmime A, Lescuyer P, Tonoli D, Bielicki J, Huttner A, Pfister M. Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug Exposure. Antibiotics (Basel) 2022; 11:antibiotics11091190. [PMID: 36139969 PMCID: PMC9494977 DOI: 10.3390/antibiotics11091190] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 08/22/2022] [Accepted: 08/31/2022] [Indexed: 11/16/2022] Open
Abstract
Current dose reductions recommended for amoxicillin in patients with impaired kidney function could lead to suboptimal treatments. In a prospective, observational study in hospitalized adults with varying kidney function treated with an IV or oral dose of amoxicillin, amoxicillin concentrations were measured in 1−2 samples on the second day of treatment. Pharmacometric modelling and simulations were performed to evaluate the probability of target attainment (PTA) for 40% of the time above MIC following standard (1000 mg q6h), reduced or increased IV dosing strategies. A total of 210 amoxicillin samples was collected from 155 patients with kidney function based on a CKD-EPI of between 12 and 165 mL/min/1.73 m2. Amoxicillin clearance could be well predicted with body weight and CKD-EPI. Recommended dose adjustments resulted in a clinically relevant reduction in the PTA for the nonspecies-related PK/PD breakpoint MIC of 8 mg/L (92%, 62% and 38% with a CKD-EPI of 10, 20 and 30 mL/min/1.73 m2, respectively, versus 100% for the standard dose). For MICs ≤ 2 mg/L, PTA > 90% was reached in these patients following both reduced and standard dose regimens. Our study showed that for amoxicillin, recommended dose reductions with impaired kidney function could lead to subtherapeutic amoxicillin concentrations in hospitalized patients, especially when targeting less susceptible pathogens.
Collapse
Affiliation(s)
- Cornelis Smit
- Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children’s Hospital (UKBB), 4056 Basel, Switzerland
- Department of Clinical Pharmacy, Antonius Hospital, 8601 ZK Sneek, The Netherlands
| | - Swapnoleena Sen
- Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children’s Hospital (UKBB), 4056 Basel, Switzerland
- Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland
- Swiss Tropical and Public Health Institute, 4056 Basel, Switzerland
| | - Elodie von Dach
- Center for Clinical Research, Geneva University Hospitals and Faculty of Medicine, 1205 Geneva, Switzerland
| | - Abderrahim Karmime
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - David Tonoli
- Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - Julia Bielicki
- Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children’s Hospital (UKBB), 4056 Basel, Switzerland
- Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George’s, University of London, London SW17 0RE, UK
| | - Angela Huttner
- Center for Clinical Research, Geneva University Hospitals and Faculty of Medicine, 1205 Geneva, Switzerland
- Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland
| | - Marc Pfister
- Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children’s Hospital (UKBB), 4056 Basel, Switzerland
- Certara, Princeton, NJ 08540, USA
- Correspondence: ; Tel.: +41-61-704-1212
| |
Collapse
|
5
|
Raptis CE, Andrey DO, Polysopoulos C, Berger C, Ciurea A, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Moeller B, Vuilleumier N, Finckh A, Rubbert-Roth A. OP0175 TYPE OF mRNA COVID-19 VACCINE AND TREATMENT INFLUENCE ANTIBODY KINETICS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients on immunomodulatory treatments mount an attenuated immune response following mRNA COVID-19 vaccination, yet long-term studies of vaccine-induced anti-SARS-CoV-2 antibody (Ab) kinetics are missing.ObjectivesIn this prospective observational study, we mapped the humoral antibody response to mRNA COVID-19 vaccines up to 24 weeks post full vaccination in patients with inflammatory rheumatic diseases (IRDs). We aimed to assess differences due to treatment, age, past SARS-CoV-2 infection, and vaccine (BNT162b2 vs. mRNA-1273).MethodsAdult patients from the SCQM cohort who assented to an mRNA COVID-19 vaccine were recruited between 3/21 – 9/21. Participants answered questionnaires via an app and received kits for the self-collection of capillary blood samples at baseline, 4, 12, and 24 weeks post full vaccination. Samples were tested for IgG Ab against the S1 domain of the SARS-CoV-2 spike protein (anti-S1-IgG) using the EUROIMMUN ELISA. To examine differences in Ab titres arising from the defined parameters, while accounting for inter-assay variability, mixed effects continuous outcome logistic regression models were applied at each timepoint.ResultsSamples were obtained from 570 patients: 67% female, mean age 53 y (SD 12 y) with 37% RA, 36% axSpA, 21% PsA, and 6% UA (undifferentiated arthritis), on no medication (no DMARDs & no glucocorticoids; 15%), csDMARDs (10%), TNFi (48%), IL-1/6/17/23i (14%), JAKi (6%), rituximab (RTX; 4%), or abatacept (ABA; 2%) in mono/combination therapy at the first vaccination. 10% of patients had a past SARS-CoV-2 infection, 54% received BNT162b2, 46% mRNA-1273.For any Ab threshold, the odds of having a higher Ab titre at 4, 12, and 24 weeks post full vaccination were 3.3 – 4 times higher with mRNA-1273 compared to BNT162b2 (Table 1, Figure 1). TNFi, JAKi, RTX, and ABA as monotherapy resulted in significantly lower Ab levels compared to no medication at almost all timepoints. In combination therapy, TNFi, IL-1/6/17/23i, RTX, and csDMARDs led to consistently lower Ab titres at all timepoints compared to respective monotherapy.Table 1.The OR of being above a given Ab threshold, regardless of the threshold. Ref. levels: mean age, no medication, no past SARS-CoV-2 inf., BNT162b2. Included in model but not shown: diagnosis, infrequently used medication (all non-signif.)Weeks post full vacc.41224OR (95% CI); pAge0.96 (0.94 – 0.97)****0.98 (0.96 – 0.996)*0.98 (0.97 – 1.00)mRNA-1273 (vs BNT162b2)3.28 (2.34 – 4.61)****3.96 (2.83 – 5.54)****3.94 (2.93 – 5.50)****Past COVID inf. (vs none)7.56 (4.32 – 13.2)****8.14 (4.78 – 13.86)****11.65 (6.62 – 20.50)****csDMARD†1.27 (0.67 – 2.41)1.78 (0.94 – 3.35)1.70 (0.86 – 3.36)TNFi†0.46 (0.28 – 0.71)****0.30 (0.19 – 0.48)****0.13 (0.081 – 0.22)****IL-1/6/17/23i†0.97 (0.54 – 1.75)1.04 (0.57 – 1.89)0.89 (0.49 – 1.64)JAKi†0.38 (0.16 – 0.91)*0.38 (0.16 – 0.91)*0.53 (0.22 – 1.28)RTX†0.078 (0.013 – 0.46)**0.078 (0.015 – 0.42)**0.16 (0.037 – 0.71)*ABA†0.14 (0.039 – 0.51)**0.087 (0.022 – 0.35)***0.068 (0.017 – 0.27)***Interactions§Age:vaccine‡1.04 (1.02 – 1.07)**1.02 (0.99 – 1.05)1.03 (1.0008 – 1.058)*csDMARD:combi0.12 (0.02 – 0.70)*0.17 (0.029 – 0.95)*0.11 (0.023 – 0.56)**TNFi:combi0.34 (0.20 – 0.59)***0.37 (0.22 – 0.61)***0.36 (0.21 – 0.62)***IL-1/6/17/23i:combi0.26 (0.09 – 0.78)*0.25 (0.085 – 0.70)**0.20 (0.071 – 0.58)**JAKi:combi1.76 (0.33 – 9.44)1.23 (0.32 – 4.70)0.95 (0.25 – 3.65)RTX:combi0.11 (0.01 – 0.87)*0.095 (0.012 – 0.73)*0.085 (0.0091 – 0.79)*ABA:combi1.75 (0.25 – 12.2)0.74 (0.096 – 5.75)0.51 (0.073 – 3.62)* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001;†Medication as monoth. vs no medication‡Interaction terms showing how OR of mRNA-1273 (vs BNT162b2) increases with age§Interaction terms with medications: medication in combination th. vs medication as monoth.ConclusionCompared to no medication, some immunomodulatory therapies resulted in markedly lower Ab levels at all timepoints. In IRD patients, a past SARS-CoV-2 infection resulted in strikingly increased immunogenicity, as did mRNA-1273 compared to BNT162b2.AcknowledgementsThis study is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM thanks the patients for their participation in this study. A list of rheumatology offices and hospitals that contribute to the SCQM registries can be found on www.scqm.ch/institutions. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors.Disclosure of InterestsCatherine Elizabeth Raptis Grant/research support from: The study presented in the abstract is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors, Diego Olivier Andrey: None declared, Christos Polysopoulos Grant/research support from: The study presented in the abstract is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors, Christoph Berger: None declared, Adrian Ciurea: None declared, Pierre Lescuyer: None declared, Tanja Maletic Grant/research support from: The study presented in the abstract is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors, Myriam Riek Grant/research support from: The study presented in the abstract is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors, Almut Scherer Grant/research support from: The study presented in the abstract is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors, Isabell von Loga Grant/research support from: The study presented in the abstract is investigator-initiated and received independent financial support from Moderna Switzerland GmbH. The SCQM is financially supported by pharmaceutical industries and donors. A list of financial supporters can be found on www.scqm.ch/sponsors, Judith Safford: None declared, Kim Lauper Speakers bureau: Kim Lauper reports consulting fees for Pfizer and speakers fees for Pfizer, Viatris and Celltrion outside of the submitted work., Consultant of: Kim Lauper reports consulting fees for Pfizer and speakers fees for Pfizer, Viatris and Celltrion outside of the submitted work., Burkhard Moeller: None declared, Nicolas Vuilleumier: None declared, Axel Finckh Speakers bureau: Axel Finckh has received consultancies or speaker honoraria for AbbVie, BMS, Eli-Lilly, Gilead, Pfizer, Sanofi, and UCB outside of the submitted work, Consultant of: Axel Finckh has received consultancies or speaker honoraria for AbbVie, BMS, Eli-Lilly, Gilead, Pfizer, Sanofi, and UCB outside of the submitted work, Grant/research support from: Axel Finckh has received research support from AbbVie, Eli-Lilly, Galapagos, and Pfizer outside of the submitted work, Andrea Rubbert-Roth: None declared
Collapse
|
6
|
Marti C, Stirnemann J, Lescuyer P, Tonoli D, von Dach E, Huttner A. Therapeutic drug monitoring and clinical outcomes in severely ill patients receiving amoxicillin: a single-center prospective cohort study. Int J Antimicrob Agents 2022; 59:106601. [DOI: 10.1016/j.ijantimicag.2022.106601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 04/07/2022] [Accepted: 04/28/2022] [Indexed: 11/05/2022]
|
7
|
Visconti G, Olesti E, González-Ruiz V, Glauser G, Tonoli D, Lescuyer P, Vuilleumier N, Rudaz S. Erratum to "Internal calibration as an emerging approach for endogenous analyte quantification: Application to steroids" [Talanta (2022) 123149]. Talanta 2022:123288. [PMID: 35304010 DOI: 10.1016/j.talanta.2022.123288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Gioele Visconti
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland
| | - Eulalia Olesti
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Víctor González-Ruiz
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Gaëtan Glauser
- Neuchâtel Platform of Analytical Chemistry, University of Neuchâtel, Avenue de Bellevaux 51, 2000 Neuchâtel, Switzerland
| | - David Tonoli
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Nicolas Vuilleumier
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva 4, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland.
| |
Collapse
|
8
|
Tagliente N, Lescuyer P, Moreau V, Collet TH, Genton L. [Vitamin deficiencies in the adult outpatient setting]. Rev Med Suisse 2022; 18:445-452. [PMID: 35266345 DOI: 10.53738/revmed.2022.18.772.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Since their discovery more than a century ago to this day, vitamins went from misunderstood molecules with mysterious properties to fundamental components with undoubted clinical implications. Despite the scientific progresses in the understanding of their physiopathological role, vitamins raise to this day multiple interrogations in clinical practice. This article aims at answering questions that are frequently encountered in the outpatient setting regarding vitamin deficiencies: who to screen ? At what moment ? By which test ? How to interpret the results ? How to supplement ? By answering these questions, we hope to provide the general practitioners with a pragmatic tool to guide them in the management of issues related to vitamins.
Collapse
Affiliation(s)
- Nikolaos Tagliente
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Pierre Lescuyer
- Service de médecine de laboratoire, Département diagnostique, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Vicky Moreau
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Tinh-Hai Collet
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Laurence Genton
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
9
|
Nguyen A, Finci L, Berney T, Tonoli D, Lescuyer P, Jayo M, Brossier Pressacco C, van Delden C, Neofytos D. Letermovir for cytomegalovirus primary prophylaxis in a multiple abdominal/small bowel transplant recipient. Clin Transplant 2022; 36:e14624. [PMID: 35235221 DOI: 10.1111/ctr.14624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Revised: 02/09/2022] [Accepted: 02/17/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Aude Nguyen
- Service des Maladies Infectieuses, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Leon Finci
- Service de Transplantation Chirurgicale, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Thierry Berney
- Service de Transplantation Chirurgicale, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - David Tonoli
- Service de Toxicologie, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Pierre Lescuyer
- Service de Toxicologie, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Murielle Jayo
- Service de Toxicologie, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | | | - Christian van Delden
- Service des Maladies Infectieuses, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Dionysios Neofytos
- Service des Maladies Infectieuses, Hôpitaux Universitaires de Genève, Genève, Switzerland
| |
Collapse
|
10
|
Visconti G, Olesti E, González-Ruiz V, Glauser G, Tonoli D, Lescuyer P, Vuilleumier N, Rudaz S. Internal calibration as an emerging approach for endogenous analyte quantification: Application to steroids. Talanta 2021; 240:123149. [PMID: 34954616 DOI: 10.1016/j.talanta.2021.123149] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 10/20/2021] [Accepted: 10/21/2021] [Indexed: 12/15/2022]
Abstract
The use of mass spectrometry methods with triple quadrupole instruments is well established for quantification. However, the preparation of calibration curves can be time-consuming and prone to analytical errors. In this study, an innovative internal calibration (IC) approach using a one-standard calibration with a stable isotope-labeled (SIL) standard version of the endogenous compound was developed. To ensure optimal quantitative performance, the following parameters were evaluated: the stability of the analyte-to-SIL response factor (RF), the chemical and isotopic purities of the SIL, and the instrumental reproducibility. Using six clinically important endogenous steroids and their respective SIL standards, we demonstrated that RFs obtained on different LC-MS platforms were consistent. The quantitative performance of the proposed approach was determined using quality control samples prepared in depleted serum, and showed both satisfactory precision (1.3%-12.4%) and trueness (77.5%-107.0%, with only 3 values outside ±30%). The developed method was then applied to human serum samples, and the results were similar to those obtained with the conventional quantification approach based on external calibration: the Passing-Bablok regression showed a proportional bias of 6.8% and a mean difference of -5.9% between the two methodologies. Finally, we showed that the naturally occurring isotopes of the SIL can be used to provide additional calibration points and increase the accuracy for analytes with low concentrations.
Collapse
Affiliation(s)
- Gioele Visconti
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland
| | - Eulalia Olesti
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Víctor González-Ruiz
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Gaëtan Glauser
- Neuchâtel Platform of Analytical Chemistry, University of Neuchâtel, Avenue de Bellevaux 51, 2000 Neuchâtel, Switzerland
| | - David Tonoli
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Nicolas Vuilleumier
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU - Rue Michel-Servet 1, 1211, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland.
| |
Collapse
|
11
|
Piletta-Zanin A, De Mul A, Rock N, Lescuyer P, Samer CF, Rodieux F. Case Report: Low Hematocrit Leading to Tacrolimus Toxicity. Front Pharmacol 2021; 12:717148. [PMID: 34483924 PMCID: PMC8415261 DOI: 10.3389/fphar.2021.717148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 08/04/2021] [Indexed: 11/13/2022] Open
Abstract
Tacrolimus is a calcineurin inhibitor characterized by a narrow therapeutic index and high intra- and inter-individual pharmacokinetic variability. Therapeutic drug monitoring in whole-blood is the standard monitoring procedure. However, tacrolimus extensively binds to erythrocytes, and tacrolimus whole-blood distribution and whole-blood trough concentrations are strongly affected by hematocrit. High whole-blood tacrolimus concentrations at low hematocrit may result in high unbound plasma concentrations and increased toxicity. We present the case of a 16-year-old girl with kidney and liver transplant in whom low concentrations of tacrolimus in the context of low hematocrit led to significant increase in the dosage of tacrolimus and participate, along with a genetic polymorphism of ABCB1, in nephrotoxicity.
Collapse
Affiliation(s)
- Alexandre Piletta-Zanin
- Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland
- Division of Pediatric Specialties, Department of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
| | - Aurélie De Mul
- Division of Pediatric Specialties, Department of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
- Pediatric Nephrology Unit, Department of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
| | - Nathalie Rock
- Division of Pediatric Specialties, Department of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
- Swiss Pediatric Liver Center, Department of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland
| | - Caroline F. Samer
- Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Frédérique Rodieux
- Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
12
|
Kofanova O, Bellora C, Aguilar-Quesada R, Bulla A, Panadero-Fajardo S, Keipes M, Shea K, Stone M, Lescuyer P, Betsou F. Corrigendum to "IL8 and EDEM3 gene expression ratio indicates peripheral blood mononuclear cell (PBMC) quality" [Journal of Immunological Methods 465 (2019) 13-19]. J Immunol Methods 2020; 478:112733. [PMID: 31916985 DOI: 10.1016/j.jim.2019.112733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Olga Kofanova
- Integrated Biobank of Luxembourg, 1 rue Louis Rech, 3555 Dudelange, Luxembourg; International Society for Biological and Environmental Repositories (ISBER), Biospecimen Science Working Group, Canada
| | - Camille Bellora
- Integrated Biobank of Luxembourg, 1 rue Louis Rech, 3555 Dudelange, Luxembourg
| | - Rocio Aguilar-Quesada
- Biobanco del Sistema Sanitario Público de Andalucía (SSPA Biobank), Avda. del Conocimiento s/n 18016, Granada, Spain; International Society for Biological and Environmental Repositories (ISBER), Biospecimen Science Working Group, Canada
| | - Alexandre Bulla
- Service de Médecine de Laboratoire, Hôpitaux Universitaires de Genève, 1211 Genève 14, Switzerland; International Society for Biological and Environmental Repositories (ISBER), Biospecimen Science Working Group, Canada
| | - Sonia Panadero-Fajardo
- Biobanco del Sistema Sanitario Público de Andalucía (SSPA Biobank), Avda. del Conocimiento s/n 18016, Granada, Spain
| | - Marc Keipes
- ZithaGesondheetsZentrum, 36 rue Zithe, 2763, Luxembourg
| | - Kathi Shea
- Precision for Medicine, 8425 Progress Drive, Frederick, MD 21701, USA; International Society for Biological and Environmental Repositories (ISBER), Biospecimen Science Working Group, Canada
| | - Mars Stone
- Blood Systems Research Institute, 270 Masonic Ave., San Francisco, CA 94118, USA; International Society for Biological and Environmental Repositories (ISBER), Biospecimen Science Working Group, Canada
| | - Pierre Lescuyer
- Service de Médecine de Laboratoire, Hôpitaux Universitaires de Genève, 1211 Genève 14, Switzerland
| | - Fay Betsou
- Integrated Biobank of Luxembourg, 1 rue Louis Rech, 3555 Dudelange, Luxembourg; International Society for Biological and Environmental Repositories (ISBER), Biospecimen Science Working Group, Canada.
| |
Collapse
|
13
|
Lassout O, Hartmer R, Jabs W, Clerici L, Tsybin YO, Samii K, Vuilleumier N, Hochstrasser D, Scherl A, Lescuyer P, Coelho Graça D. Clinical method evaluation of hemoglobin S and C identification by top-down selected reaction monitoring and electron transfer dissociation. Clin Proteomics 2019; 16:41. [PMID: 31889938 PMCID: PMC6915975 DOI: 10.1186/s12014-019-9261-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 11/26/2019] [Indexed: 01/21/2023] Open
Abstract
Background Biological diagnosis of hemoglobin disorders is a complex process relying on the combination of several analytical techniques to identify Hb variants in a particular sample. Currently, hematology laboratories usually use high-performance liquid chromatography (HPLC), capillary electrophoresis and gel-based methods to characterize Hb variants. Co-elution and co-migration may represent major issues for precise identification of Hb variants, even for the most common ones such as Hb S and C. Methods We adapted a top-down selected reaction monitoring (SRM) electron transfer dissociation (ETD) mass spectrometry (MS) method to fit with a clinical laboratory environment. An automated analytical process with semi-automated data analysis compatible with a clinical practice was developed. A comparative study between a reference HPLC method and the MS assay was performed on 152 patient samples. Results The developed workflow allowed to identify with high specificity and selectivity the most common Hb variants (Hb S and Hb C). Concordance of the MS-based approach with HPLC was 71/71 (100%) for Hb S and 11/11 (100%) for Hb C. Conclusions This top-down SRM ETD method can be used in a clinical environment to detect Hb S and Hb C.
Collapse
Affiliation(s)
- Olivier Lassout
- 1Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | | | | | - Lorella Clerici
- 2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | - Yury O Tsybin
- 4Spectroswiss, EPFL Innovation Park, Lausanne, Switzerland
| | - Kaveh Samii
- 2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland.,5Division of Hematology, Geneva University Hospitals, Geneva, Switzerland
| | - Nicolas Vuilleumier
- 1Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | - Denis Hochstrasser
- 1Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | - Alexander Scherl
- 1Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | - Pierre Lescuyer
- 1Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| | - Didia Coelho Graça
- 1Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,2Division of Laboratory Medicine, Department of Laboratory Medicine, Genetics and Pathology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
| |
Collapse
|
14
|
Gagnebin Y, Pezzatti J, Lescuyer P, Boccard J, Ponte B, Rudaz S. Combining the advantages of multilevel and orthogonal partial least squares data analysis for longitudinal metabolomics: Application to kidney transplantation. Anal Chim Acta 2019; 1099:26-38. [PMID: 31986274 DOI: 10.1016/j.aca.2019.11.050] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 11/15/2019] [Accepted: 11/21/2019] [Indexed: 11/29/2022]
Abstract
Kidney transplantation is one of the renal replacement options in patients suffering from end-stage renal disease (ESRD). After a transplant, patient follow-up is essential and is mostly based on immunosuppressive drug levels control, creatinine measurement and kidney biopsy in case of a rejection suspicion. The extensive analysis of metabolite levels offered by metabolomics might improve patient monitoring, help in the surveillance of the restoration of a "normal" renal function and possibly also predict rejection. The longitudinal follow-up of those patients with repeated measurements is useful to understand changes and decide whether an intervention is necessary. The time modality, therefore, constitutes a specific dimension in the data structure, requiring dedicated consideration for proper statistical analysis. The handling of specific data structures in metabolomics has received strong interest in recent years. In this work, we demonstrated the recently developed ANOVA multiblock OPLS (AMOPLS) to efficiently analyse longitudinal metabolomic data by considering the intrinsic experimental design. Indeed, AMOPLS combines the advantages of multilevel approaches and OPLS by separating between and within individual variations using dedicated predictive components, while removing most uncorrelated variations in the orthogonal component(s), thus facilitating interpretation. This modelling approach was applied to a clinical cohort study aiming to evaluate the impact of kidney transplantation over time on the plasma metabolic profile of graft patients and donor volunteers. A dataset of 266 plasma metabolites was identified using an LC-MS multiplatform analytical setup. Two separate AMOPLS models were computed: one for the recipient group and one for the donor group. The results highlighted the benefits of transplantation for recipients and the relatively low impacts on blood metabolites of donor volunteers.
Collapse
Affiliation(s)
- Yoric Gagnebin
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Julian Pezzatti
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Pierre Lescuyer
- Department of Genetic and Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Julien Boccard
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Belen Ponte
- Service of Nephrology, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Serge Rudaz
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
| |
Collapse
|
15
|
Coelho Graça D, Lescuyer P. Ultrahigh Performance Mass Spectrometry in Clinical Chemistry: A Taste of the Future? Clin Chem 2019; 65:943-945. [DOI: 10.1373/clinchem.2019.305631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Accepted: 05/20/2019] [Indexed: 11/06/2022]
Affiliation(s)
- Didia Coelho Graça
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
- Department of Medicine, Faculty of Medicine, Geneva University, Geneva, Switzerland
| |
Collapse
|
16
|
Cosset E, Locatelli M, Marteyn A, Lescuyer P, Dall Antonia F, Mor FM, Preynat-Seauve O, Stoppini L, Tieng V. Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases. J Vis Exp 2019. [PMID: 31305527 DOI: 10.3791/59682] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
The lack of relevant in vitro neural models is an important obstacle on medical progress for neuropathologies. Establishment of relevant cellular models is crucial both to better understand the pathological mechanisms of these diseases and identify new therapeutic targets and strategies. To be pertinent, an in vitro model must reproduce the pathological features of a human disease. However, in the context of neurodegenerative disease, a relevant in vitro model should provide neural cell replacement as a valuable therapeutic opportunity. Such a model would not only allow screening of therapeutic molecules but also can be used to optimize neural protocol differentiation [for example, in the context of transplantation in Parkinson's disease (PD)]. This study describes two in vitro protocols of 1) human glioblastoma development within a human neural organoids (NO) and 2) neuron dopaminergic (DA) differentiation generating a three-dimensional (3D) organoid. For this purpose, a well-standardized protocol was established that allows the production of size-calibrated neurospheres derived from human embryonic stem cell (hESC) differentiation. The first model can be used to reveal molecular and cellular events occurring during in glioblastoma development within the neural organoid, while the DA organoid not only represents a suitable source of DA neurons for cell therapy in Parkinson's disease but also can be used for drug testing.
Collapse
Affiliation(s)
- Erika Cosset
- Laboratory of Tumor Immunology, Translational Research Center in Onco-Hematology, Department of Internal Medicine Specialties, Faculty of Medicine, University of Geneva;
| | - Manon Locatelli
- Department of Pathology and Immunology, University Medical Center, University of Geneva
| | - Antoine Marteyn
- Department of Pathology and Immunology, University Medical Center, University of Geneva
| | - Pierre Lescuyer
- Laboratory of Toxicology and Therapeutic Drug Monitoring, Geneva University Hospitals
| | - Florence Dall Antonia
- Laboratory of Toxicology and Therapeutic Drug Monitoring, Geneva University Hospitals
| | - Flavio Maurizio Mor
- Tissue Engineering Laboratory, Hepia/HES-SO, University of Applied Sciences Western Switzerland
| | - Olivier Preynat-Seauve
- Laboratory of Experimental cell therapy, Department of Diagnostics, Geneva University Hospitals
| | - Luc Stoppini
- Tissue Engineering Laboratory, Hepia/HES-SO, University of Applied Sciences Western Switzerland
| | - Vannary Tieng
- Department of Pathology and Immunology, University Medical Center, University of Geneva
| |
Collapse
|
17
|
Jaques DA, Spahr L, Berra G, Poffet V, Lescuyer P, Gerstel E, Garin N, Martin PY, Ponte B. Biomarkers for acute kidney injury in decompensated cirrhosis: A prospective study. Nephrology (Carlton) 2019; 24:170-180. [PMID: 29369449 DOI: 10.1111/nep.13226] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/15/2018] [Indexed: 12/14/2022]
Abstract
AIM Acute kidney injury (AKI) is a frequent complication in cirrhotic patients. As serum creatinine is a poor marker of renal function in this population, we aimed to study the utility of several biomarkers in this context. METHODS A prospective study was conducted in hospitalized patients with decompensated cirrhosis. Serum creatinine (SCr), Cystatin C (CystC), NGAL and urinary NGAL, KIM-1, protein, albumin and sodium were measured on three separate occasions. Renal resistive index (RRI) was obtained. We analyzed the value of these biomarkers to determine the presence of AKI, its aetiology [prerenal, acute tubular necrosis (ATN), or hepatorenal (HRS)], its severity and a composite clinical outcome at 30 days (death, dialysis and intensive care admission). RESULTS We included 105 patients, of which 55 had AKI. SCr, CystC, NGAL (plasma and urinary), urinary sodium and RRI at inclusion were independently associated with the presence of AKI. SCr, CystC and plasma NGAL were able to predict the subsequent development of AKI. Pre-renal state showed lower levels of SCr, NGAL (plasma and urinary) and RRI. ATN patients had high levels of NGAL (plasma and urinary) as well as urinary protein and sodium. HRS patients presented an intermediate pattern. All biomarkers paralleled the severity of AKI. SCr, CystC and plasma NGAL predicted the development of the composite clinical outcome with the same performance as the MELD score. CONCLUSIONS In patients with decompensated cirrhosis, early measurement of renal biomarkers provides valuable information on AKI aetiology. It could also improve AKI diagnosis and prognosis.
Collapse
Affiliation(s)
- David A Jaques
- Internal Medicine Department, Geneva University Hospitals, Geneva, Switzerland
| | - Laurent Spahr
- Gastroenterology Division, Medicine Specialties Department, Geneva University Hospitals, Geneva, Switzerland
| | - Gregory Berra
- Internal Medicine Department, Geneva University Hospitals, Geneva, Switzerland
| | - Vincent Poffet
- Internal Medicine Department, Geneva University Hospitals, Geneva, Switzerland
| | - Pierre Lescuyer
- Biobank of the Division of Laboratory Medicine, Department of Genetic and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Eric Gerstel
- Internal Medicine Department, Geneva University Hospitals, Geneva, Switzerland.,La Colline Clinic, Geneva, Switzerland
| | - Nicolas Garin
- Internal Medicine Department, Geneva University Hospitals, Geneva, Switzerland
| | - Pierre-Yves Martin
- Nephrology Division, Medicine Specialties Department, Geneva University Hospitals, Geneva, Switzerland
| | - Belen Ponte
- Nephrology Division, Medicine Specialties Department, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
18
|
Kofanova O, Henry E, Aguilar Quesada R, Bulla A, Navarro Linares H, Lescuyer P, Shea K, Stone M, Tybring G, Bellora C, Betsou F. IL8 and IL16 levels indicate serum and plasma quality. Clin Chem Lab Med 2019; 56:1054-1062. [PMID: 29425105 DOI: 10.1515/cclm-2017-1047] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Accepted: 12/30/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND Longer pre-centrifugation times alter the quality of serum and plasma samples. Markers for such delays in sample processing and hence for the sample quality, have been identified. METHODS Twenty cytokines in serum, EDTA plasma and citrate plasma samples were screened for changes in concentration induced by extended blood pre-centrifugation delays at room temperature. The two cytokines that showed the largest changes were further validated for their "diagnostic performance" in identifying serum or plasma samples with extended pre-centrifugation times. RESULTS In this study, using R&D Systems ELISA kits, EDTA plasma samples and serum samples with a pre-centrifugation delay longer than 24 h had an IL16 concentration higher than 313 pg/mL, and an IL8 concentration higher than 125 pg/mL, respectively. EDTA plasma samples with a pre-centrifugation delay longer than 48 h had an IL16 concentration higher than 897 pg/mL, citrate plasma samples had an IL8 concentration higher than 21.5 pg/mL and serum samples had an IL8 concentration higher than 528 pg/mL. CONCLUSIONS These robust and accurate tools, based on simple and commercially available ELISA assays can greatly facilitate qualification of serum and plasma legacy collections with undocumented pre-analytics.
Collapse
Affiliation(s)
- Olga Kofanova
- Integrated Biobank of Luxembourg, Strassen, Luxembourg
| | - Estelle Henry
- Integrated Biobank of Luxembourg, Strassen, Luxembourg
| | | | - Alexandre Bulla
- Sérothèque Centrale, Département de Médecine Génétique et de Laboratoire, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | | | - Pierre Lescuyer
- Sérothèque Centrale, Département de Médecine Génétique et de Laboratoire, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - Kathi Shea
- Precision for Medicine, Frederick, MD, USA
| | - Mars Stone
- Blood Systems Research Institute, San Francisco, CA, USA
| | | | | | - Fay Betsou
- Integrated Biobank of Luxembourg, Strassen, Luxembourg
| |
Collapse
|
19
|
Gagnebin Y, Pezzatti J, Lescuyer P, Boccard J, Ponte B, Rudaz S. Toward a better understanding of chronic kidney disease with complementary chromatographic methods hyphenated with mass spectrometry for improved polar metabolome coverage. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1116:9-18. [PMID: 30951967 DOI: 10.1016/j.jchromb.2019.03.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 03/19/2019] [Accepted: 03/25/2019] [Indexed: 12/25/2022]
Abstract
The prevalence of chronic kidney disease (CKD) is increasing worldwide. New technical approaches are needed to improve early diagnosis, disease understanding and patient monitoring, and to evaluate new therapies. Metabolomics, as a prime candidate in the field of CKD research, aims to comprehensively analyze the metabolic complexity of biological systems. An extensive analysis of the metabolites contained in biofluids is therefore needed, and the combination of data obtained from multiple analytical platforms constitutes a promising methodological approach. This study presents an original workflow based on complementary chromatographic conditions, reversed-phase and hydrophilic interaction chromatography hyphenated to mass spectrometry to improve the polar metabolome coverage coupled with a univocal metabolite annotation strategy enabling a rapid access to the biological interpretation. This multiplatform workflow was applied in a CKD cohort study to assess plasma metabolic profile modifications related to renal disease. Multivariate analysis of 278 endogenous annotated metabolites enabled patient stratification with respect to CKD stages and helped to generate new biological insights, while also confirming the relevance of tryptophan metabolism pathway in this condition.
Collapse
Affiliation(s)
- Yoric Gagnebin
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Julian Pezzatti
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Julien Boccard
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; Swiss Center of Human Applied Toxicology, University of Basel, Switzerland
| | - Belén Ponte
- Service of Nephrology, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; Swiss Center of Human Applied Toxicology, University of Basel, Switzerland.
| |
Collapse
|
20
|
Kofanova O, Bellora C, Quesada RA, Bulla A, Panadero-Fajardo S, Keipes M, Shea K, Stone M, Lescuyer P, Betsou F. IL8 and EDEM3 gene expression ratio indicates peripheral blood mononuclear cell (PBMC) quality. J Immunol Methods 2019; 465:13-19. [DOI: 10.1016/j.jim.2018.11.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 11/19/2018] [Accepted: 11/19/2018] [Indexed: 10/27/2022]
|
21
|
Steiner C, Lescuyer P, Tille JC, Cutler P, Ducret A. Development of a Highly Multiplexed SRM Assay for Biomarker Discovery in Formalin-Fixed Paraffin-Embedded Tissues. Methods Mol Biol 2019; 1959:185-203. [PMID: 30852824 DOI: 10.1007/978-1-4939-9164-8_13] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
The search for novel and clinically relevant biomarkers still represents a major clinical challenge and mass-spectrometry-based technologies are essential tools to help in this process. In this application, we demonstrate how selected reaction monitoring (SRM) can be applied in a highly multiplexed way to analyze formalin-fixed paraffin-embedded (FFPE) tissues. Such an assay can be used to analyze numerous samples for narrowing down a list of potential biomarkers to the most relevant candidates. The use of FFPE tissues is of high relevance in this context as large sample collections linked with valuable clinical information are available in hospitals around the world. Here we describe in detail how we proceeded to develop such an assay for 200 proteins in breast tumor FFPE tissues. We cover the selection of suitable peptides, which are different in FFPE compared to fresh frozen tissues and show how we deliberately biased our assay toward proteins with a high probability of being measurable in human clinical samples.
Collapse
Affiliation(s)
- Carine Steiner
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
- Biomarkers, Bioinformatics and Omics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.
- Late Stage Analytical Development, Small Molecules Technical Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
- Clinical Proteomics and Chemistry Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | | | - Paul Cutler
- Biomarkers, Bioinformatics and Omics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland
- Translational Biomarkers and Bioanalysis, Development Sciences, UCB Pharma, Slough, UK
| | - Axel Ducret
- Biomarkers, Bioinformatics and Omics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland
| |
Collapse
|
22
|
Coelho Graça D, Hartmer R, Jabs W, Scherl A, Clerici L, Samii K, Tsybin YO, Hochstrasser D, Lescuyer P. Detection of Proteoforms Using Top-Down Mass Spectrometry and Diagnostic Ions. Methods Mol Biol 2019; 1959:173-183. [PMID: 30852823 DOI: 10.1007/978-1-4939-9164-8_12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Characterization of protein structure modifications is an important field in mass spectrometry (MS)-based proteomics. Here, we describe a process to quickly and reliably identify a mass change in a targeted protein sequence by top-down mass spectrometry (TD MS) using electron transfer dissociation (ETD). The step-by-step procedure describes how to develop a TD MS method for data acquisition as well as the data analysis process. The described TD MS workflow utilizes diagnostic ions to characterize an unknown sample in a few hours.
Collapse
Affiliation(s)
- Didia Coelho Graça
- Clinical Proteomics and Chemistry Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Department of Genetic, Laboratory Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland.
| | | | - Wolfgang Jabs
- Beuth Hochschule für Technik Berlin, Berlin, Germany
| | - Alexander Scherl
- Clinical Proteomics and Chemistry Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Department of Genetic, Laboratory Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland
| | - Lorella Clerici
- Department of Genetic, Laboratory Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland
| | - Kaveh Samii
- Department of Genetic, Laboratory Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland
- Division of Hematology, Geneva University Hospitals, Geneva, Switzerland
| | | | - Denis Hochstrasser
- Clinical Proteomics and Chemistry Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Department of Genetic, Laboratory Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland
| | - Pierre Lescuyer
- Clinical Proteomics and Chemistry Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Department of Genetic, Laboratory Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
23
|
Bricheux A, Lenggenhager L, Hughes S, Karmime A, Lescuyer P, Huttner A. Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study. Clin Microbiol Infect 2018; 25:383.e1-383.e4. [PMID: 30528370 DOI: 10.1016/j.cmi.2018.11.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2018] [Revised: 11/16/2018] [Accepted: 11/19/2018] [Indexed: 10/27/2022]
Abstract
OBJECTIVES Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is increasingly employed to ensure adequate antibiotic exposure and slow emergence of resistance. Imipenem's therapeutic range has not been defined; we report plasma concentrations and clinical outcomes of patients receiving imipenem for bacterial infections. METHODS All hospitalized adult patients undergoing imipenem TDM during therapy for suspected or confirmed bacterial infections between 1 January 2013 and 28 February 2017 were included in this single-centre retrospective cohort. The primary outcome was incidence of clinical toxicity; secondary outcomes included incidence of clinical failure and median imipenem concentrations in those with and without toxicity and/or failure. Total imipenem concentrations were measured via high-performance liquid chromatography with ultraviolet detection. RESULTS A total of 403 imipenem levels were drawn from 300 patients. Fifteen (5%) patients experienced an adverse event considered at least possibly related to imipenem. Eighty-eight (29%) patients had clinical failure; augmented renal clearance appeared to emerge as a protective factor against failure (OR 0.42; 95% CI 0.20-0.89). Median first-measure trough concentration was 3.2 mg/L (IQR 1.7-6.5). Patients with suspected toxicity did not have higher concentrations. Patients whose dose was not increased after a trough level <2 mg/L was returned trended towards increased clinical failure (3/28 (11%) vs. 12/63 (19%)), though the difference was not statistically significant. CONCLUSIONS Toxicity was rare and clinical failure frequent in this cohort of patients whose imipenem concentrations were generally low and occasionally undetectable. Larger trials are needed to define optimal imipenem exposure.
Collapse
Affiliation(s)
- A Bricheux
- Geneva University Faculty of Medicine, Geneva, Switzerland
| | - L Lenggenhager
- Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - S Hughes
- Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Geneva, Switzerland
| | - A Karmime
- Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Geneva, Switzerland
| | - P Lescuyer
- Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Geneva, Switzerland
| | - A Huttner
- Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
| |
Collapse
|
24
|
Joye T, Sidibe J, Déglon J, Karmime A, Sporkert F, Favrat B, Lescuyer P, Augsburger M, Thomas A. Évaluation du prélèvement de sang sur papier buvard analysé par UHPLC-HRMS pour le criblage large échelle de drogues et de médicaments. Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.04.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Hirtz C, Bros P, Brede C, Lescuyer P, Maceski AM, Vialaret J, Delatour V, Lehmann S. Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. Crit Rev Clin Lab Sci 2018; 55:346-358. [DOI: 10.1080/10408363.2018.1470159] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Christophe Hirtz
- CHU Montpellier, IRMB, Hôpital Saint Eloi, LBPC et CRB, University of Montpellier, Montpellier, France
| | - Pauline Bros
- CHU Montpellier, IRMB, Hôpital Saint Eloi, LBPC et CRB, University of Montpellier, Montpellier, France
- Laboratoire National de Métrologie et d'Essais (LNE), Paris, France
| | - Cato Brede
- Stavanger University Hospital, Avdeling for Medisinsk Biokjemi, Stavanger, Norway
| | - Pierre Lescuyer
- Laboratoire de Toxicologie et de Suivi Thérapeutique des Médicaments, Service de Médecine de Laboratoire, Hôpitaux Universitaires de Genève, Gèneve, Switzerland
| | - Aleksandra M. Maceski
- CHU Montpellier, IRMB, Hôpital Saint Eloi, LBPC et CRB, University of Montpellier, Montpellier, France
| | - Jerome Vialaret
- CHU Montpellier, IRMB, Hôpital Saint Eloi, LBPC et CRB, University of Montpellier, Montpellier, France
| | - Vincent Delatour
- Laboratoire National de Métrologie et d'Essais (LNE), Paris, France
| | - Sylvain Lehmann
- CHU Montpellier, IRMB, Hôpital Saint Eloi, LBPC et CRB, University of Montpellier, Montpellier, France
| |
Collapse
|
26
|
Gagnebin Y, Pezzati J, Lescuyer P, Martinez C, De Seigneux S, Boccard J, Rudaz S, Ponte B. FO040TOWARDS A BETTER UNDERSTANDING OF KIDNEY DISEASE USING METABOLOMICS. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.fo040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Yoric Gagnebin
- School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland
| | - Julian Pezzati
- School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland
| | - Pierre Lescuyer
- Department of GEnetic and Laboratory Medicine, University Hospital of Geneva, Geneva, Switzerland
| | | | | | - Julien Boccard
- School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland
| | - Belen Ponte
- Nephrology, University Hospital of Geneva, Geneva, Switzerland
| |
Collapse
|
27
|
Coelho Graça D, Golaz O, Magnin JL, Fleurkens H, Rossier MF, Lescuyer P, Vuilleumier N. CRP-Based Cardiovascular Risk Assessment: New Conventional CRP Assay Fit for Purpose? J Appl Lab Med 2018; 2:952-959. [PMID: 33636832 DOI: 10.1373/jalm.2017.025403] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 01/22/2018] [Indexed: 11/06/2022]
Abstract
BACKGROUND Subclinical inflammation was shown to play a role in the context of cardiovascular disorder processes. American College of Cardiology/American Heart Association guidelines on cardiovascular risk assessment in specific clinical contexts recommend the use of C-reactive protein (CRP) measurement with high sensitive (hs)-CRP assays that meet the precision requirements for values <2 mg/L. Until now, only hs-CRP assays reached the required limit of quantification. However, new regular CRP assays allow measuring CRP down to 0.6 mg/L. METHODS A multisite comparative study between hs-CRP and a new conventional CRP assay (Tina-quant) was performed to evaluate the possibility of using regular CRP assays for cardiovascular risk assessment. RESULTS A satisfactory concordance was observed between regular CRP assays and the hs-CRP assay. Both assays met the analytical precision requirements at the different cutpoints tested (1.00, 2.00, and 3.00 mg/L). CONCLUSION These results suggest that this new regular CRP assay can be used for cardiovascular risk assessment, which is expected to provide substantial operational and financial advantages when compared with hs-CRP assays.
Collapse
Affiliation(s)
- Didia Coelho Graça
- Department of Genetic Medicine, Laboratory and Pathology, Geneva University Hospitals, Geneva, Switzerland.,Department of Human Protein Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
| | - Olivier Golaz
- Department of Genetic Medicine, Laboratory and Pathology, Geneva University Hospitals, Geneva, Switzerland
| | - Jean-Luc Magnin
- Central Laboratory, HFR-Fribourg Hôpital Cantonal, Fribourg, Switzerland
| | - Hans Fleurkens
- Service of Clinical Chemistry and Toxicology, ICH, Hospital of Valais, Sion, Switzerland
| | - Michel F Rossier
- Department of Human Protein Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland.,Service of Clinical Chemistry and Toxicology, ICH, Hospital of Valais, Sion, Switzerland
| | - Pierre Lescuyer
- Department of Genetic Medicine, Laboratory and Pathology, Geneva University Hospitals, Geneva, Switzerland.,Department of Human Protein Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
| | - Nicolas Vuilleumier
- Department of Genetic Medicine, Laboratory and Pathology, Geneva University Hospitals, Geneva, Switzerland.,Department of Human Protein Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
| |
Collapse
|
28
|
Lehmann S, Brede C, Lescuyer P, Cocho JA, Vialaret J, Bros P, Delatour V, Hirtz C. Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold? Clin Chim Acta 2017; 467:51-58. [DOI: 10.1016/j.cca.2016.06.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2015] [Revised: 05/30/2016] [Accepted: 06/01/2016] [Indexed: 01/08/2023]
|
29
|
Gagnebin Y, Tonoli D, Lescuyer P, Ponte B, de Seigneux S, Martin PY, Schappler J, Boccard J, Rudaz S. Metabolomic analysis of urine samples by UHPLC-QTOF-MS: Impact of normalization strategies. Anal Chim Acta 2017; 955:27-35. [DOI: 10.1016/j.aca.2016.12.029] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 12/08/2016] [Accepted: 12/20/2016] [Indexed: 10/20/2022]
|
30
|
Huwyler T, Lenggenhager L, Abbas M, Ing Lorenzini K, Hughes S, Huttner B, Karmime A, Uçkay I, von Dach E, Lescuyer P, Harbarth S, Huttner A. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect 2017; 23:454-459. [PMID: 28111294 DOI: 10.1016/j.cmi.2017.01.005] [Citation(s) in RCA: 90] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Revised: 12/05/2016] [Accepted: 01/06/2017] [Indexed: 10/20/2022]
Abstract
OBJECTIVES Cefepime remains an important antibiotic for severe bacterial infections, yet some meta-analyses have shown elevated mortality among patients randomized to it. Therapeutic drug monitoring (TDM) of β-lactam antibiotics is increasing, but optimal plasma concentrations remain unknown. We examined clinical outcomes of patients undergoing cefepime TDM in an initial effort to define the drug's toxicity threshold. METHODS In this single-centre retrospective cohort study, we enrolled all adult hospitalized patients receiving cefepime and undergoing TDM from January 2013 through July 2016. The primary outcome was the incidence of clinical toxicity; a secondary outcome was clinical failure. Plasma samples were analysed via high-performance liquid chromatography with ultraviolet detection. RESULTS A total of 161 cefepime concentrations were drawn from 93 patients. Roughly half (82/161, 51%) and one-third (49/161, 30%) were trough and steady-state levels from patients receiving intermittent and continuous infusions, respectively; median concentrations were 17.6 mg/L (IQR 9.7-35.2) and 29.2 mg/L (IQR 18.9-45.9). Ten patients (11%) experienced a neurologic event considered at least possibly related to cefepime; neurotoxicity was associated with poorer renal function (median creatinine clearance 54 (IQR 39-97) vs. 75 mL/min/1.732 (IQR 44-104)) and longer cefepime durations (mean 8.3 (SD±6.7) vs. 13.3 days (± 14.2), p = 0.071). Patients with trough levels >20 mg/L had a fivefold higher risk for neurologic events (OR 5.05, 95% CI 1.3-19.8). CONCLUSIONS Neurotoxicity potentially related to cefepime occurred at plasma concentrations >35 mg/L. For those receiving intermittent infusions, trough concentrations >20 mg/L should be avoided until further information is available from prospective studies.
Collapse
Affiliation(s)
- T Huwyler
- University of Geneva School of Medicine, Geneva, Switzerland
| | - L Lenggenhager
- University of Geneva School of Medicine, Geneva, Switzerland
| | - M Abbas
- Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - K Ing Lorenzini
- Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - S Hughes
- Toxicology Laboratory, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - B Huttner
- Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - A Karmime
- Toxicology Laboratory, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - I Uçkay
- Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - E von Dach
- Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - P Lescuyer
- Toxicology Laboratory, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - S Harbarth
- Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - A Huttner
- Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| |
Collapse
|
31
|
Acosta-Martin AE, Antinori P, Uppugunduri CRS, Daali Y, Ansari M, Scherl A, Müller M, Lescuyer P. Detection of busulfan adducts on proteins. Rapid Commun Mass Spectrom 2016; 30:2517-2528. [PMID: 27599297 DOI: 10.1002/rcm.7730] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 08/26/2016] [Accepted: 08/29/2016] [Indexed: 06/06/2023]
Abstract
RATIONALE Busulfan is a bifunctional alkyl sulfonate antineoplastic drug. This alkylating agent was described as forming covalent adducts on proteins. However, only limited data are available regarding the interaction of busulfan with proteins. Mass spectrometry and bioinformatics were used to identify busulfan adducts on human serum albumin and hemoglobin. METHODS Albumin and hemoglobin were incubated with busulfan or control compounds, digested with trypsin and analyzed by liquid chromatography/tandem mass spectrometry (LC/MS/MS) on a Thermo Fisher LTQ Orbitrap Velos Pro. MS data were used to generate spectral libraries of non-modified peptides and an open modification search was performed to identify potential adduct mass shifts and possible modification sites. Results were confirmed by a second database search including identified mass shifts and by visual inspection of annotated tandem mass spectra of adduct-carrying peptides. RESULTS Five structures of busulfan adducts were detected and a chemical structure could be attributed to four of them. Two were primary adducts corresponding to busulfan monoalkylation and alkylation of two amino acid residues by a single busulfan molecule. Two others corresponded to secondary adducts generated during sample processing. Adducts were mainly detected on Asp, Glu, and His residues. These findings were confirmed by subsequent database searches and experiments with synthetic peptides. CONCLUSIONS The combination of in vitro incubation of proteins with the drug of interest or control compounds, high-resolution mass spectrometry, and open modification search allowed confirmation of the direct interaction of busulfan with proteins and characterization of the resulting adducts. Our results also showed that careful analysis of the data is required to detect experimental artifacts. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Adelina E Acosta-Martin
- Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Paola Antinori
- Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Swiss Centre of Applied Human Toxicology, Geneva, Switzerland
| | - Chakradhara Rao S Uppugunduri
- Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland
- Cansearch Research Laboratory, Geneva Medical University, Geneva, Switzerland
| | - Youssef Daali
- Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland
| | - Marc Ansari
- Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland
- Cansearch Research Laboratory, Geneva Medical University, Geneva, Switzerland
| | - Alexander Scherl
- Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
- Swiss Centre of Applied Human Toxicology, Geneva, Switzerland
| | - Markus Müller
- SIB-Swiss Institute of Bioinformatics, University of Geneva, Switzerland
| | - Pierre Lescuyer
- Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
32
|
Carbone F, Satta N, Burger F, Roth A, Lenglet S, Pagano S, Lescuyer P, Bertolotto M, Spinella G, Pane B, Palombo D, Pende A, Dallegri F, Mach F, Vuilleumier N, Montecucco F. Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. Vascul Pharmacol 2016; 85:57-65. [DOI: 10.1016/j.vph.2016.08.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 05/17/2016] [Accepted: 08/14/2016] [Indexed: 11/25/2022]
|
33
|
Vuilleumier N, Simona A, Méan M, Limacher A, Lescuyer P, Gerstel E, Bounameaux H, Aujesky D, Righini M. Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism. PLoS One 2016; 11:e0155973. [PMID: 27219621 PMCID: PMC4878757 DOI: 10.1371/journal.pone.0155973] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 05/06/2016] [Indexed: 11/21/2022] Open
Abstract
Biomarkers unrelated to myocardial necrosis, such as cystatin C, copeptin, and mid-regional pro-adrenomedullin (MR-proADM), showed promise for cardiovascular risk prediction. Knowing whether they are comparable to cardiac biomarkers such as high-sensitive cardiac-troponin T (hs-cTnT) or N-terminal pro-Brain natriuretic peptide (NT-proBNP) in elderly patients with acute non-massive pulmonary embolism (NMPE) remains elusive. This study aims at comparing the prognostic accuracy of cardiac and non-cardiac biomarkers in patients with NMPE aged ≥65 years over time. In the context of the SWITCO65+ cohort, we evaluated 227 elderly patients with an available blood sample taken within one day from diagnosis. The primary study endpoint was defined as PE-related mortality and the secondary endpoint as PE-related complications. The biomarkers’ predictive ability at 1, 3, 12 and 24 months was determined using C-statistics and Cox regression. For both study endpoints, C-statistics (95% confidence interval) were stable over time for all biomarkers, with the highest value for hs-cTnT, ranging between 0.84 (0.68–1.00) and 0.80 (0.70–0.90) for the primary endpoint, and between 0.74 (0.63–0.86) and 0.65 (0.57–0.73) for the secondary endpoint. For both study endpoints, cardiac biomarkers were found to be independently associated with risk, NT-proBNP displaying a negative predictive value of 100%. Among non-cardiac biomarkers, only copeptin and MR-proADM were independent predictors of PE-related mortality but they were not independent predictors of PE-related complications, and displayed lower negative predictive values. In elderly NMPE patients, cardiac biomarkers appear to be valuable prognostic to identify very low-risk individuals. Trial Registration: ClinicalTrials.gov NCT00973596
Collapse
Affiliation(s)
- Nicolas Vuilleumier
- Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Aurélien Simona
- Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
- * E-mail:
| | - Marie Méan
- Division of General Internal Medicine, Bern University Hospital and University of Bern, Bern, Switzerland
- Service of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Andreas Limacher
- CTU Bern, Department of Clinical Research and Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
| | - Pierre Lescuyer
- Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Eric Gerstel
- Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
- Clinique de la Colline, Geneva, Switzerland
| | - Henri Bounameaux
- Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Drahomir Aujesky
- Division of General Internal Medicine, Bern University Hospital and University of Bern, Bern, Switzerland
| | - Marc Righini
- Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| |
Collapse
|
34
|
Bulla A, De Witt B, Ammerlaan W, Betsou F, Lescuyer P. Blood DNA Yield but Not Integrity or Methylation Is Impacted After Long-Term Storage. Biopreserv Biobank 2016; 14:29-38. [PMID: 26812548 DOI: 10.1089/bio.2015.0045] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Collection of human whole blood for genomic DNA extraction is part of numerous clinical studies. Since DNA extraction cannot always be performed at the time of sample collection, whole blood samples may be stored for years before being processed. The use of appropriate storage conditions is then critical to obtain DNA in sufficient quantity and of adequate quality in order to obtain reliable results from the subsequent molecular biological analyses. In this study, EDTA whole blood samples were collected from 8 healthy volunteers, and different durations (up to 1 year) and temperatures (room temperature, 4°C, -20°C, and -80°C) of storage were compared. The effect of the addition of a DNA preservative agent was also assessed before and after storage. DNA concentrations measured by UV spectrophotometry and spectrofluorometry were used to calculate DNA extraction yields and double-strand DNA ratios. DNA integrity was controlled by agarose gel electrophoresis and long-range polymerase chain reaction. The impact of storage conditions on DNA methylation was also evaluated. Results showed that certain storage conditions have a significant impact on the DNA extraction yield but little or no effect on DNA integrity and methylation. Storage of EDTA blood at -80°C guarantees high-quality DNA with a good yield. Higher DNA extraction yields were obtained with the addition of a DNA preservative agent before thawing EDTA blood stored at -20°C or -80°C. Long-term storage at room temperature in the presence of a DNA preservative agent also appeared to be a reliable procedure.
Collapse
Affiliation(s)
- Alexandre Bulla
- 1 Sérothèque Centrale, Département de Médecine Génétique et de Laboratoire, Hôpitaux Universitaires de Genève , Geneva, Switzerland
| | | | | | - Fay Betsou
- 2 Integrated Biobank of Luxembourg , Luxembourg
| | - Pierre Lescuyer
- 1 Sérothèque Centrale, Département de Médecine Génétique et de Laboratoire, Hôpitaux Universitaires de Genève , Geneva, Switzerland
| |
Collapse
|
35
|
Trezzi JP, Bulla A, Bellora C, Rose M, Lescuyer P, Kiehntopf M, Hiller K, Betsou F. LacaScore: a novel plasma sample quality control tool based on ascorbic acid and lactic acid levels. Metabolomics 2016; 12:96. [PMID: 27199628 PMCID: PMC4848344 DOI: 10.1007/s11306-016-1038-1] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Accepted: 04/05/2016] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Metabolome analysis is complicated by the continuous dynamic changes of metabolites in vivo and ex vivo. One of the main challenges in metabolomics is the robustness and reproducibility of results, partially driven by pre-analytical variations. OBJECTIVES The objective of this study was to analyse the impact of pre-centrifugation time and temperature, and to determine a quality control marker in plasma samples. METHODS Plasma metabolites were measured by gas chromatography-mass spectrometry (GC-MS) and analysed with the MetaboliteDetector software. The metabolites, which were the most labile to pre-analytical variations, were further measured by enzymatic assays. A score was calculated for their use as quality control markers. RESULTS The pre-centrifugation temperature was shown to be critical in the stability of plasma samples and had a significant impact on metabolite concentration profiles. In contrast, pre-centrifugation delay had only a minor impact. Based on the results of this study, whole blood should be kept on wet ice and centrifuged within maximum 3 h as a prerequisite for preparing EDTA plasma samples fit for the purpose of metabolome analysis. CONCLUSIONS We have established a novel blood sample quality control marker, the LacaScore, based on the ascorbic acid to lactic acid ratio in plasma, which can be used as an indicator of the blood pre-centrifugation conditions, and hence the suitability of the sample for metabolome analyses. This method can be applied in research institutes and biobanks, enabling assessment of the quality of their plasma sample collections.
Collapse
Affiliation(s)
- Jean-Pierre Trezzi
- />Integrated Biobank of Luxembourg, 6 rue Ernest Barble, 1210 Luxembourg, Luxembourg
- />Luxembourg Centre for Systems Biomedicine, 7, Avenue des Hauts-Fourneaux, 4362 Esch-Belval, Luxembourg
| | - Alexandre Bulla
- />Sérothèque Centrale, Département de Médecine Génétique et de Laboratoire, Hôpitaux Universitaires de Geneve, 1211 Geneve 14, Switzerland
- />International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group, Vancouver, Canada
| | - Camille Bellora
- />Integrated Biobank of Luxembourg, 6 rue Ernest Barble, 1210 Luxembourg, Luxembourg
| | - Michael Rose
- />Institute of Clinical Chemistry and Laboratory Diagnostics and Integrierte BioBank Jena (IBBJ), Jena University Hospital, Erlanger Allee 101, 07740 Jena, Germany
| | - Pierre Lescuyer
- />Sérothèque Centrale, Département de Médecine Génétique et de Laboratoire, Hôpitaux Universitaires de Geneve, 1211 Geneve 14, Switzerland
| | - Michael Kiehntopf
- />Institute of Clinical Chemistry and Laboratory Diagnostics and Integrierte BioBank Jena (IBBJ), Jena University Hospital, Erlanger Allee 101, 07740 Jena, Germany
- />International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group, Vancouver, Canada
| | - Karsten Hiller
- />Luxembourg Centre for Systems Biomedicine, 7, Avenue des Hauts-Fourneaux, 4362 Esch-Belval, Luxembourg
| | - Fay Betsou
- />Integrated Biobank of Luxembourg, 6 rue Ernest Barble, 1210 Luxembourg, Luxembourg
- />International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group, Vancouver, Canada
| |
Collapse
|
36
|
Steiner C, Tille JC, Lamerz J, Kux van Geijtenbeek S, McKee TA, Venturi M, Rubbia-Brandt L, Hochstrasser D, Cutler P, Lescuyer P, Ducret A. Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues. Mol Cell Proteomics 2015; 14:2786-99. [PMID: 26149442 DOI: 10.1074/mcp.o115.049049] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Indexed: 11/06/2022] Open
Abstract
The ability to accurately quantify proteins in formalin-fixed paraffin-embedded tissues using targeted mass spectrometry opens exciting perspectives for biomarker discovery. We have developed and evaluated a selectedreaction monitoring assay for the human receptor tyrosine-protein kinase erbB-2 (HER2) in formalin-fixed paraffin-embedded breast tumors. Peptide candidates were identified using an untargeted mass spectrometry approach in relevant cell lines. A multiplexed assay was developed for the six best candidate peptides and evaluated for linearity, precision and lower limit of quantification. Results showed a linear response over a calibration range of 0.012 to 100 fmol on column (R(2): 0.99-1.00).The lower limit of quantification was 0.155 fmol on column for all peptides evaluated. The six HER2 peptides were quantified by selected reaction monitoring in a cohort of 40 archival formalin-fixed paraffin-embedded tumor tissues from women with invasive breast carcinomas, which showed different levels of HER2 gene amplification as assessed by standard methods used in clinical pathology. The amounts of the six HER2 peptides were highly and significantly correlated with each other, indicating that peptide levels can be used as surrogates of protein amounts in formalin-fixed paraffin-embedded tissues. After normalization for sample size, selected reaction monitoring peptide measurements were able to correctly predict 90% of cases based on HER2 amplification as defined by the American Society of Clinical Oncology and College of American Pathologists. In conclusion, the developed assay showed good analytical performance and a high agreement with immunohistochemistry and fluorescence in situ hybridization data. This study demonstrated that selected reaction monitoring allows to accurately quantify protein expression in formalin-fixed paraffin-embedded tissues and represents therefore a powerful approach for biomarker discovery studies. The untargeted mass spectrometry data is available via ProteomeXchange whereas the quantification data by selected reaction monitoring is available on the Panorama Public website.
Collapse
Affiliation(s)
- Carine Steiner
- From the ‡Division of Laboratory Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland; §Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland;
| | - Jean-Christophe Tille
- ¶Division of Clinical Pathology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland
| | - Jens Lamerz
- §Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Sabine Kux van Geijtenbeek
- §Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Thomas A McKee
- ¶Division of Clinical Pathology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland
| | - Miro Venturi
- ‖Oncology Division, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Nonnenwald 2, D-82377 Penzberg, Germany
| | - Laura Rubbia-Brandt
- ¶Division of Clinical Pathology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland
| | - Denis Hochstrasser
- From the ‡Division of Laboratory Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland
| | - Paul Cutler
- §Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Pierre Lescuyer
- From the ‡Division of Laboratory Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland
| | - Axel Ducret
- §Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| |
Collapse
|
37
|
Vuilleumier N, Limacher A, Méan M, Choffat J, Lescuyer P, Bounameaux H, Aujesky D, Righini M. Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism. J Intern Med 2015; 277:707-16. [PMID: 25285747 DOI: 10.1111/joim.12316] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVE To determine the prognostic accuracy of cardiac biomarkers alone and in combination with clinical scores in elderly patients with non-high-risk pulmonary embolism (PE). DESIGN Ancillary analysis of a Swiss multicentre prospective cohort study. SUBJECTS A total of 230 patients aged ≥65 years with non-high-risk PE. MAIN OUTCOME MEASURES The study end-point was a composite of PE-related complications, defined as PE-related death, recurrent venous thromboembolism or major bleeding during a follow-up of 30 days. The prognostic accuracy of the Pulmonary Embolism Severity Index (PESI), the Geneva Prognostic Score (GPS), the precursor of brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) was determined using sensitivity, specificity, predictive values, receiver operating characteristic (ROC) curve analysis, logistic regression and reclassification statistics. RESULTS The overall complication rate during follow-up was 8.7%. hs-cTnT achieved the highest prognostic accuracy [area under the ROC curve: 0.75, 95% confidence interval (CI): 0.63-0.86, P < 0.001). At the predefined cut-off values, the negative predictive values of the biomarkers were above 95%. For levels above the cut-off, the risk of complications increased fivefold for hs-cTnT [odds ratio (OR): 5.22, 95% CI: 1.49-18.25] and 14-fold for NT-proBNP (OR: 14.21, 95% CI: 1.73-116.93) after adjustment for both clinical scores and renal function. Reclassification statistics indicated that adding hs-cTnT to the GPS or the PESI significantly improved the prognostic accuracy of both clinical scores. CONCLUSION In elderly patients with nonmassive PE, NT-proBNP or hs-cTnT could be an adequate alternative to clinical scores for identifying low-risk individuals suitable for outpatient management.
Collapse
Affiliation(s)
- N Vuilleumier
- Faculty of Medicine, Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland
| | - A Limacher
- Clinical Trials Unit (CTU) Bern, Department of Clinical Research and Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
| | - M Méan
- Division of General Internal Medicine, Bern University Hospital and University of Bern, Bern, Switzerland
| | - J Choffat
- Faculty of Medicine, Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland
| | - P Lescuyer
- Faculty of Medicine, Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland
| | - H Bounameaux
- Faculty of Medicine, Division of Angiology and Haemostasis, Geneva University Hospital, Geneva, Switzerland
| | - D Aujesky
- Division of General Internal Medicine, Bern University Hospital and University of Bern, Bern, Switzerland
| | - M Righini
- Faculty of Medicine, Division of Angiology and Haemostasis, Geneva University Hospital, Geneva, Switzerland
| |
Collapse
|
38
|
Coelho Graça D, Hartmer R, Jabs W, Beris P, Clerici L, Stoermer C, Samii K, Hochstrasser D, Tsybin YO, Scherl A, Lescuyer P. Identification of hemoglobin variants by top-down mass spectrometry using selected diagnostic product ions. Anal Bioanal Chem 2015; 407:2837-45. [DOI: 10.1007/s00216-015-8525-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Revised: 01/23/2015] [Accepted: 01/27/2015] [Indexed: 11/25/2022]
|
39
|
Abstract
The study of bile proteins could improve the understanding of physiological processes involved in the regulation of the hepato-biliary system. Researchers have tried for years to investigate the bile proteome but, until recently, only a few tens of proteins were known. The advent of proteomics, availing of large-scale analytical devices paired with potent bioinformatic resources, lately allowed the identification of thousands of proteins in bile. Nevertheless, the knowledge of their role in the hepato-biliary system still represents almost a "blank page in the book of physiology." In this review, we first guide the reader through the historical phases of the analysis of bile protein content, emphasizing the recent progresses achieved through the use of proteomic techniques. Thereafter, we deeply explore the involvement of bile proteins in health and disease, with a particular focus on the discovery of biomarkers for biliary tract malignancies.
Collapse
Affiliation(s)
- Annarita Farina
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva, Switzerland
| | | | | | | |
Collapse
|
40
|
Steiner C, Ducret A, Tille JC, Thomas M, McKee TA, Rubbia-Brandt L, Scherl A, Lescuyer P, Cutler P. Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues. Proteomics 2014; 14:441-51. [PMID: 24339433 PMCID: PMC4265304 DOI: 10.1002/pmic.201300311] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 11/04/2013] [Accepted: 11/11/2013] [Indexed: 12/12/2022]
Abstract
Proteomic analysis of tissues has advanced in recent years as instruments and methodologies have evolved. The ability to retrieve peptides from formalin-fixed paraffin-embedded tissues followed by shotgun or targeted proteomic analysis is offering new opportunities in biomedical research. In particular, access to large collections of clinically annotated samples should enable the detailed analysis of pathologically relevant tissues in a manner previously considered unfeasible. In this paper, we review the current status of proteomic analysis of formalin-fixed paraffin-embedded tissues with a particular focus on targeted approaches and the potential for this technique to be used in clinical research and clinical diagnosis. We also discuss the limitations and perspectives of the technique, particularly with regard to application in clinical diagnosis and drug discovery.
Collapse
Affiliation(s)
- Carine Steiner
- Division of Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland; Human Protein Sciences Department, University of Geneva, Geneva, Switzerland; Translational Technologies and Bioinformatics, Pharma Research and Early Development, F. Hoffmann-La Roche AG, Basel, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Rabilloud T, Lescuyer P. Proteomics in mechanistic toxicology: History, concepts, achievements, caveats, and potential. Proteomics 2014; 15:1051-74. [DOI: 10.1002/pmic.201400288] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Revised: 07/25/2014] [Accepted: 08/25/2014] [Indexed: 12/19/2022]
Affiliation(s)
- Thierry Rabilloud
- Laboratory of Chemistry and Biology of Metals; CNRS UMR; 5249 Grenoble France
- Laboratory of Chemistry and Biology of Metals; Université Grenoble Alpes; Grenoble France
- Laboratory of Chemistry and Biology of Metals; CEA Grenoble; iRTSV/CBM; Grenoble France
| | - Pierre Lescuyer
- Department of Human Protein Sciences; Clinical Proteomics and Chemistry Group; Geneva University; Geneva Switzerland
- Toxicology and Therapeutic Drug Monitoring Laboratory; Department of Genetic and Laboratory Medicine; Geneva University Hospitals; Geneva Switzerland
| |
Collapse
|
42
|
Ammerlaan W, Trezzi JP, Lescuyer P, Mathay C, Hiller K, Betsou F. Method validation for preparing serum and plasma samples from human blood for downstream proteomic, metabolomic, and circulating nucleic acid-based applications. Biopreserv Biobank 2014; 12:269-80. [PMID: 25075813 DOI: 10.1089/bio.2014.0003] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Formal method validation for biospecimen processing in the context of accreditation in laboratories and biobanks is lacking. Serum and plasma processing protocols were validated for fitness-for-purpose in terms of key downstream endpoints, and this article demonstrates methodology for biospecimen processing method validation. METHODS Serum and plasma preparation from human blood was optimized for centrifugation conditions with respect to microparticle counts. Optimal protocols were validated for methodology and reproducibility in terms of acceptance criteria based on microparticle counts, DNA and hemoglobin concentration, and metabolomic and proteomic profiles. These parameters were also used to evaluate robustness for centrifugation temperature (4°C versus room temperature [RT]), deceleration (low, medium, high) and blood stability (after a 2-hour delay). RESULTS Optimal protocols were 10-min centrifugation for serum and 20-min for plasma at 2000 g, medium brake, RT. Methodology and reproducibility acceptance criteria were met for both protocols except for reproducibility of plasma metabolomics. Overall, neither protocol was robust for centrifugation at 4°C versus RT. RT gave higher microparticles and free DNA yields in serum, and fewer microparticles with less hemolysis in plasma. Overall, both protocols were robust for fast, medium, and low deceleration, with a medium brake considered optimal. Pre-centrifugation stability after a 2-hour delay was seen at both temperatures for hemoglobin concentration and proteomics, but not for microparticle counts. CONCLUSIONS We validated serum and plasma collection methods suitable for downstream protein, metabolite, or free nucleic acid-based applications. Temperature and pre-centrifugation delay can influence analytic results, and laboratories and biobanks should systematically record these conditions in the scope of accreditation.
Collapse
Affiliation(s)
- Wim Ammerlaan
- 1 Integrated BioBank of Luxembourg (IBBL) , Luxembourg
| | | | | | | | | | | |
Collapse
|
43
|
Rabilloud T, Lescuyer P. The proteomic to biology inference, a frequently overlooked concern in the interpretation of proteomic data: a plea for functional validation. Proteomics 2014; 14:157-61. [PMID: 24273051 DOI: 10.1002/pmic.201300413] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Revised: 11/11/2013] [Accepted: 11/13/2013] [Indexed: 11/08/2022]
Abstract
Proteomics will celebrate its 20th year in 2014. In this relatively short period of time, it has invaded most areas of biology and its use will probably continue to spread in the future. These two decades have seen a considerable increase in the speed and sensitivity of protein identification and characterization, even from complex samples. Indeed, what was a challenge twenty years ago is now little more than a daily routine. Although not completely over, the technological challenge now makes room to another challenge, which is the best possible appraisal and exploitation of proteomic data to draw the best possible conclusions from a biological point of view. The point developed in this paper is that proteomic data are almost always fragmentary. This means in turn that although better than an mRNA level, a protein level is often insufficient to draw a valid conclusion from a biological point of view, especially in a world where PTMs play such an important role. This means in turn that transformation of proteomic data into biological data requires an important intermediate layer of functional validation, i.e. not merely the confirmation of protein abundance changes by other methods, but a functional appraisal of the biological consequences of the protein level changes highlighted by the proteomic screens.
Collapse
Affiliation(s)
- Thierry Rabilloud
- CNRS UMR 5249, Laboratory of Chemistry and Biology of Metals, Grenoble, France; Univ. Grenoble Alpes, Laboratory of Chemistry and Biology of Metals, Grenoble, France; CEA Grenoble, iRTSV/CBM, Laboratory of Chemistry and Biology of Metals, Grenoble, France
| | | |
Collapse
|
44
|
O'Seaghdha CM, Wu H, Yang Q, Kapur K, Guessous I, Zuber AM, Köttgen A, Stoudmann C, Teumer A, Kutalik Z, Mangino M, Dehghan A, Zhang W, Eiriksdottir G, Li G, Tanaka T, Portas L, Lopez LM, Hayward C, Lohman K, Matsuda K, Padmanabhan S, Firsov D, Sorice R, Ulivi S, Brockhaus AC, Kleber ME, Mahajan A, Ernst FD, Gudnason V, Launer LJ, Mace A, Boerwinckle E, Arking DE, Tanikawa C, Nakamura Y, Brown MJ, Gaspoz JM, Theler JM, Siscovick DS, Psaty BM, Bergmann S, Vollenweider P, Vitart V, Wright AF, Zemunik T, Boban M, Kolcic I, Navarro P, Brown EM, Estrada K, Ding J, Harris TB, Bandinelli S, Hernandez D, Singleton AB, Girotto G, Ruggiero D, d'Adamo AP, Robino A, Meitinger T, Meisinger C, Davies G, Starr JM, Chambers JC, Boehm BO, Winkelmann BR, Huang J, Murgia F, Wild SH, Campbell H, Morris AP, Franco OH, Hofman A, Uitterlinden AG, Rivadeneira F, Völker U, Hannemann A, Biffar R, Hoffmann W, Shin SY, Lescuyer P, Henry H, Schurmann C, Munroe PB, Gasparini P, Pirastu N, Ciullo M, Gieger C, März W, Lind L, Spector TD, Smith AV, Rudan I, Wilson JF, Polasek O, Deary IJ, Pirastu M, Ferrucci L, Liu Y, Kestenbaum B, Kooner JS, Witteman JCM, Nauck M, Kao WHL, Wallaschofski H, Bonny O, Fox CS, Bochud M. Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations. PLoS Genet 2013; 9:e1003796. [PMID: 24068962 PMCID: PMC3778004 DOI: 10.1371/journal.pgen.1003796] [Citation(s) in RCA: 118] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2013] [Accepted: 07/29/2013] [Indexed: 01/08/2023] Open
Abstract
Calcium is vital to the normal functioning of multiple organ systems and its serum concentration is tightly regulated. Apart from CASR, the genes associated with serum calcium are largely unknown. We conducted a genome-wide association meta-analysis of 39,400 individuals from 17 population-based cohorts and investigated the 14 most strongly associated loci in ≤21,679 additional individuals. Seven loci (six new regions) in association with serum calcium were identified and replicated. Rs1570669 near CYP24A1 (P = 9.1E-12), rs10491003 upstream of GATA3 (P = 4.8E-09) and rs7481584 in CARS (P = 1.2E-10) implicate regions involved in Mendelian calcemic disorders: Rs1550532 in DGKD (P = 8.2E-11), also associated with bone density, and rs7336933 near DGKH/KIAA0564 (P = 9.1E-10) are near genes that encode distinct isoforms of diacylglycerol kinase. Rs780094 is in GCKR. We characterized the expression of these genes in gut, kidney, and bone, and demonstrate modulation of gene expression in bone in response to dietary calcium in mice. Our results shed new light on the genetics of calcium homeostasis. Calcium is vital to many biological processes and its serum concentration is tightly regulated. Family studies have shown that serum calcium is under strong genetic control. Apart from CASR, the genes associated with serum calcium are largely unknown. We conducted a genome-wide association meta-analysis of 39,400 individuals from 17 population-based cohorts and investigated the 14 most strongly associated loci in ≤21,679 additional individuals. We identified seven loci (six new regions) as being robustly associated with serum calcium. Three loci implicate regions involved in rare monogenic diseases including disturbances of serum calcium levels. Several of the newly identified loci harbor genes linked to the hormonal control of serum calcium. In mice experiments, we characterized the expression of these genes in gut, kidney, and bone, and explored the influence of dietary calcium intake on the expression of these genes in these organs. Our results shed new light on the genetics of calcium homeostasis and suggest a role for dietary calcium intake in bone-specific gene expression.
Collapse
Affiliation(s)
- Conall M O'Seaghdha
- National Heart, Lung, and Blood Institute's Framingham Heart Study and Center for Population Studies, Framingham, Massachusetts, United States of America ; Renal Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Acosta-Martin AE, Coelho Graça D, Antinori P, Clerici L, Hartmer R, Meyer M, Hochstrasser D, Samii K, Lescuyer P, Scherl A. Quantitative Mass Spectrometry Analysis of Intact Hemoglobin A2 by Precursor Ion Isolation and Detection. Anal Chem 2013; 85:7971-5. [DOI: 10.1021/ac401782t] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Adelina E. Acosta-Martin
- Department of Human Protein
Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
- Department of Genetic and Laboratory
Medicine, Geneva University Hospitals,
Geneva, Switzerland
| | - Didia Coelho Graça
- Department of Human Protein
Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
| | - Paola Antinori
- Department of Human Protein
Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
| | - Lorella Clerici
- Department of Genetic and Laboratory
Medicine, Geneva University Hospitals,
Geneva, Switzerland
| | | | | | - Denis Hochstrasser
- Department of Human Protein
Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
- Department of Genetic and Laboratory
Medicine, Geneva University Hospitals,
Geneva, Switzerland
| | - Kaveh Samii
- Division of Hematology, Geneva University Hospital, Geneva, Switzerland
| | - Pierre Lescuyer
- Department of Human Protein
Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
- Department of Genetic and Laboratory
Medicine, Geneva University Hospitals,
Geneva, Switzerland
| | - Alexander Scherl
- Department of Human Protein
Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
- Department of Genetic and Laboratory
Medicine, Geneva University Hospitals,
Geneva, Switzerland
| |
Collapse
|
46
|
Lukic N, Visentin R, Delhaye M, Frossard JL, Lescuyer P, Dumonceau JM, Farina A. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis. Biochim Biophys Acta 2013; 1844:1026-33. [PMID: 23872482 DOI: 10.1016/j.bbapap.2013.06.023] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 06/21/2013] [Accepted: 06/28/2013] [Indexed: 12/18/2022]
Abstract
Proteomics is a key tool in the identification of new bile biomarkers for differentiating malignant and nonmalignant biliary stenoses. Unfortunately, the complexity of bile and the presence of molecules interfering with protein analysis represent an obstacle for quantitative proteomic studies in bile samples. The simultaneous need to introduce purification steps and minimize the use of pre-fractionation methods inevitably leads to protein loss and limited quantifications. This dramatically reduces the chance of identifying new potential biomarkers. In the present study, we included differential centrifugation as a preliminary step in a quantitative proteomic workflow involving iTRAQ labeling, peptide fractionation by OFFGEL electrophoresis and LC-MS/MS, to compare protein expression in bile samples collected from patients with malignant or nonmalignant biliary stenoses. A total of 1267 proteins were identified, including a set of 322 newly described bile proteins, mainly belonging to high-density cellular fractions. The subsequent comparative analysis led to a 5-fold increase in the number of quantified proteins over previously published studies and highlighted 104 proteins overexpressed in malignant samples. Finally, immunoblot verifications performed on a cohort of 8 malignant (pancreatic adenocarcinoma, n=4; cholangiocarcinoma, n=4) and 5 nonmalignant samples (chronic pancreatitis, n=3; biliary stones, n=2) confirmed the results of proteomic analysis for three proteins: olfactomedin-4, syntenin-2 and Ras-related C3 botulinum toxin substrate 1. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.
Collapse
Affiliation(s)
- Natalija Lukic
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland
| | - Rémy Visentin
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland
| | - Myriam Delhaye
- Department of Gastroenterology, Erasme Hospital, Free University of Brussels, Brussels BE-1070, Belgium
| | - Jean-Louis Frossard
- Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Pierre Lescuyer
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland; Clinical Proteomics Laboratory, Department of Genetic and Laboratory Medicine, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Jean-Marc Dumonceau
- Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Annarita Farina
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland.
| |
Collapse
|
47
|
Farina A, Dumonceau JM, Antinori P, Annessi-Ramseyer I, Frossard JL, Hochstrasser DF, Delhaye M, Lescuyer P. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses. Biochim Biophys Acta 2013; 1844:1018-25. [PMID: 23806607 DOI: 10.1016/j.bbapap.2013.06.010] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 06/13/2013] [Accepted: 06/14/2013] [Indexed: 12/25/2022]
Abstract
Differentiating malignant from nonmalignant biliary stenoses is challenging. This could be facilitated by the measurement of cancer biomarkers in bile. We aimed at (i) identifying new cancer biomarkers by comparative proteomic analysis of bile collected from patients with a malignant or benign biliary stenosis (exploratory phase) and (ii) verifying the accuracy of the newly identified potential biomarkers for discriminating malignant versus nonmalignant biliary stenoses in a larger group of patients (confirmation phase). Overall, 66 proteins were found overexpressed (ratio>1.5) in at least one cancer condition using proteomic analysis and 7 proteins were increased in all malignant/nonmalignant disease comparisons. Preliminary screening by immunoblot highlighted carcinoembryonic cell adhesion molecule 6 (CEAM6), a cell surface protein overexpressed in many human cancers, as an interesting candidate biomarker. ELISA subsequently confirmed CEAM6 as a potential bile biomarker for distinguishing malignant from benign biliary stenoses with a receiver operating characteristic (ROC) area under the curve (AUC) of 0.92 (specificity 83%, sensitivity 93%, positive predictive value 93%, and negative predictive value 83%). No significant difference in serum CEAM6 level was found between malignant and nonmalignant samples. Combining bile CEAM6 and serum CA19-9 in a panel further improved diagnostic accuracy for malignant stenoses (AUC 0.96, specificity 83%, sensitivity 97%, positive predictive value 93%, and negative predictive value 91%). CEAM6 measurement in bile could be clinically useful to discriminate between malignant and nonmalignant causes of biliary stenosis. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.
Collapse
Affiliation(s)
- Annarita Farina
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland.
| | - Jean-Marc Dumonceau
- Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Paola Antinori
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland
| | - Isabelle Annessi-Ramseyer
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland; Clinical Proteomics Laboratory, Department of Genetic and Laboratory Medicine, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Jean-Louis Frossard
- Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Denis F Hochstrasser
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland; Clinical Proteomics Laboratory, Department of Genetic and Laboratory Medicine, Geneva University Hospitals, Geneva CH-1211, Switzerland
| | - Myriam Delhaye
- Department of Gastroenterology, Erasme Hospital, Free University of Brussels, Brussels BE-1070, Belgium
| | - Pierre Lescuyer
- Biomedical Proteomics Research Group, Department of Human Protein Sciences, Geneva University, Geneva CH-1211, Switzerland; Clinical Proteomics Laboratory, Department of Genetic and Laboratory Medicine, Geneva University Hospitals, Geneva CH-1211, Switzerland
| |
Collapse
|
48
|
Fétaud-Lapierre V, Pastor CM, Jorge-Costa M, Hochstrasser DF, Morel DR, Frossard JL, Lescuyer P. Time-course proteomic analysis of taurocholate-induced necrotizing acute pancreatitis. J Proteomics 2013; 85:12-27. [PMID: 23624238 DOI: 10.1016/j.jprot.2013.04.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Revised: 03/28/2013] [Accepted: 04/14/2013] [Indexed: 01/29/2023]
Abstract
UNLABELLED Acute pancreatitis is an inflammatory disease of the pancreas, which varies greatly in course and severity. Severe forms are associated with serious local and/or systemic complications, and eventually death. The pathobiology of acute pancreatitis is complex. Animal models have been developed to investigate pathobiological processes and identify factors determining disease course. We performed a time-course proteomic analysis using a rat model of severe necrotizing acute pancreatitis induced by taurocholate perfusion in the pancreatic ducts. Results showed that levels of proteins associated to a given biological process changed in a coordinated fashion after disease onset. It was possible to follow the response of a particular pathobiological process to pancreatitis induction and to compare the course of protein pathways. Proteins involved in acinar cell secretion were found to follow a different kinetics than other cellular processes. After an initial decrease, secretory pathway-associated proteins raised again at 18 h post-induction. This phenomenon coincided with a burst in the expression of pancreatitis-associated protein (REG3A), an acute phase protein produced by the exocrine pancreas, and with the decrease of classical markers of pancreatic injury, suggesting that the expression of proteins associated to the secretory pathway may be a modulating factor of pancreas injury. BIOLOGICAL SIGNIFICANCE Acute pancreatitis (AP) is a complex inflammatory disease, the pathobiology of which is not yet fully understood. Various animal models, relying on different mechanisms of disease induction, have been developed in order to investigate pathobiological processes of AP. In this study, we performed a time-course proteomic analysis to investigate changes of the pancreas proteome occurring in an experimental model of AP induced by perfusion of taurocholate, a bile acid, into the pancreatic duct. This experimental model is characterized by a severe disease with pancreatic necrosis and systemic inflammation. The objectives of this study were to determine the kinetics of functionally related proteins in the early steps of the experimental disease in order to identify protein pathways playing key roles in AP pathobiology and to correlate these data with parameters classically used to assess disease severity. The present work provides for the first time an overview of protein expression in the pancreas during the course of taurocholate-induced necrotizing AP. We believe that correlation of these results with data obtained using proteomic or biochemical approaches in various experimental models of AP will help in highlighting new features, generating hypotheses and constitute therefore a strong and reliable basis for further targeted investigations.
Collapse
Affiliation(s)
- Vanessa Fétaud-Lapierre
- Biomedical Proteomics Research Group, Department of Human Protein Science, Geneva Faculty of Medicine, Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
49
|
Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, Lescuyer P, Moll S. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteomics 2013; 82:193-229. [PMID: 23376485 DOI: 10.1016/j.jprot.2013.01.012] [Citation(s) in RCA: 111] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2012] [Revised: 12/17/2012] [Accepted: 01/03/2013] [Indexed: 12/14/2022]
Abstract
Urine results from a coordinated activity of glomerular and tubular compartments of the kidney. As a footprint of these cellular functional processes, urinary exosomes, and 40-80 nm membrane vesicles released after fusion with the plasma membrane into the extracellular environment by renal epithelial cells, are a source for identification of proteins and investigation of their role in the kidney. The aim of the present study was the identification of podocyte exosome proteins based on urine immunoabsorption using podocyte-specific CR1-immunocoated beads followed by proteomic analysis using LC MS/MS techniques. This methodology allowed the identification of 1195 proteins. By using a bioinformatic approach, 27 brain-expressed proteins were identified, in which 14 out of them were newly demonstrated to be expressed in the kidney at a mRNA level, and, one of them, the COMT protein, was demonstrated to be expressed in podocytes at a protein level. These results, attesting the reliability of the methodology to identify podocyte proteins, need now to be completed by further experiments to analyze more precisely their biological function(s) in the podocytes.
Collapse
Affiliation(s)
- Marco Prunotto
- Institute of Clinical Pathology, Geneva University Hospitals, Geneva CH-1211, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Coelho Graça D, Lescuyer P, Clerici L, Tsybin YO, Hartmer R, Meyer M, Samii K, Hochstrasser DF, Scherl A. Electron transfer dissociation mass spectrometry of hemoglobin on clinical samples. J Am Soc Mass Spectrom 2012; 23:1750-1756. [PMID: 22869297 DOI: 10.1007/s13361-012-0446-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2012] [Revised: 07/06/2012] [Accepted: 07/06/2012] [Indexed: 06/01/2023]
Abstract
A mass spectrometry-based assay combining the specificity of selected reaction monitoring and the protein ion activation capabilities of electron transfer dissociation was developed and employed for the rapid identification of hemoglobin variants from whole blood without previous proteolytic cleavage. The analysis was performed in a robust ion trap mass spectrometer operating at nominal mass accuracy and resolution. Subtle differences in globin sequences, resulting with mass shifts of about one Da, can be unambiguously identified. These results suggest that mass spectrometry analysis of entire proteins using electron transfer dissociation can be employed on clinical samples in a workflow compatible with diagnostic applications.
Collapse
Affiliation(s)
- Didia Coelho Graça
- Biomedical Proteomics Research Group, Department of Human Protein Science, Faculty of Medicine, Geneva University, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|